Intellia Therapeutics has announced early-stage clinical data suggesting that its investigational gene editing treatment may ...

But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...

Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...

Begin your TipRanks Premium journey today. Intellia Therapeutics (NTLA) Company Description: Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides ...

Intellia Therapeutics CEO John Leonard has, for the last couple years, found himself stuck in a financial Groundhog Day.

Analyst Terence Flynn of Morgan Stanley maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report), retaining the price target of $56.00. Don't Miss our Black Friday Offers: Terence ...

Intellia Therapeutics (NASDAQ: NTLA) announced some positive new clinical trial data only to see its stock slide by 18% -- ...

Cash runway is not expected to get Intellia to meaningful data readouts for their Phase III trials. See why NTLA stock is a ...

Intellia Therapeutics' NTLA-2002 Phase II results last month were underwhelming, however, management reassured investors on ...

On Wednesday, Intellia Therapeutics Inc (NTLA) stock saw a decline, ending the day at $16.11 which represents a decrease of $-0.54 or -3.24% from the prior close of $16.65. The stock opened at $16.8 ...

Lead candidates NTLA-2001 and NTLA-2002 achieved significant clinical milestones. Intellia Therapeutics reported ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.